- seekingalpha.com
- Posted On 08 November 2026
Arrowhead reports lower pancreatitis rates, early cholesterol drug results (ARWR:NASDAQ)
Worsening blood-sugar control occurred in 14% of plozasiran recipients versus 8.7% on placebo. Overall health problems occurred at similar rates in both groups,...
Source:
seekingalpha.com